Share:

Share to Twitter

Press Releases

Amarillo Blood and Marrow Transplant Program Receives Prestigious National Honor

Awarded Accreditation by Foundation for the Accreditation of Cellular Therapy
05/03/2010
The Amarillo Blood and Marrow Transplant Program (ABMTP) consisting of Texas Oncology–Amarillo Cancer Center, Northwest Texas Hospital, and Coffee Memorial Blood Center, received official accreditation by the Foundation for the Accreditation of Cellular Therapy (FACT). Amarillo patients now have access to a nationally-recognized program in their local community that provides a one-stop, total-therapy approach to patients with blood cancers.  

Accreditation is awarded to a limited number of transplant programs that demonstrate an exceptional level of patient care and medical and laboratory practices in the United States, Canada, and Australia. With the accreditation, ABMTP now has the required credentials to participate in the Cancer Trials Support Unit of the National Cancer Institute (NCI), the Eastern Cooperating Oncology Group (ECOG), and the Southwestern Oncology Group (SWOG) giving Amarillo patients access to most advanced treatments.

“FACT accreditation places the program among an elite group of blood and marrow transplant centers worldwide and highlights the outstanding quality of our program,” said Dr. Seah Lim, Texas Oncology–Amarillo Cancer Center medical oncologist and director of ABMTP. “This accreditation honors our staff in the inpatient and outpatient care units, the stem cell processing laboratory, and Coffee Memorial Blood Center for their high standards and quality work.”

FACT’s extensive on-site inspection includes every aspect of the blood stem cell transplant program, from patient care and laboratory practices to administrative systems. This inspection ensures that patients are receiving an overall quality of care that has passed rigorous standards. The transplant program replaces bone marrow stem cells that have been destroyed by high doses of chemotherapy or radiation therapy with the patient’s own non-cancerous cells (autologous) or cells from someone else (allogeneic).

Since 2001, the multidisciplinary team from the Amarillo Blood and Marrow Transplant Program has provided blood and marrow stem cell transplantation to patients, primarily those with leukemia, lymphoma, myelodysplastic syndromes, and multiple myeloma. The physicians, nurses, and staff of ABMTP remain committed to providing seamless, patient-centric service from diagnosis to the conclusion of treatment for patients with blood cancers. 

For more information about the Amarillo Blood and Marrow Transplant Program, contact Texas Oncology–Amarillo Cancer Center at 806-358-8654.